Plasminogen activator inhibitor-1 in obstructive sleep apnea patients with and without hypertension.
Obstructive sleep apnea syndrome (OSAS) is an important risk factor in cardiovascular disorders. Although the precise mechanism remains to be described, hypercoagulability seems to be involved. To test the presence of decreased fibrinolysis, we measured plasma levels of plasminogen activator inhibitor-1 (PAI-1) in 96 male subjects (32 subjects with OSAS, 32 subjects with both OSAS and hypertension, and a 32 subjects in the control group). All subjects completed a sleep questionnaire and underwent a general physical examination, biochemistry test, and polysomnography study. Patients and control subjects had similar baseline clinical characteristics for age, gender, smoking habit, and levels of cholesterol and triglycerides. Patients with OSAS presented significantly higher circulating levels of PAI-1 compared with the control group, and the difference was even more marked in patients with both OSAS and hypertension. OSAS patients presented a significant inverse correlation between PAI-1 levels and apnea-hypopnea index (r= -0.71, p<0.001). In conclusion, OSAS patients presented higher circulating levels of PAI than the control group, which was even greater when patients had associated hypertension.
Zamarrón
Carlos
C
Division of Respiratory Medicine, Hospital Clínico Universitario de Santiago, Choupana s/n, Santiago de Compostela, 15706, Spain. carlos.zamarron.sanz@sergas.es.
Ricoy
Jorge
J
Division of Respiratory Medicine, Hospital Clínico Universitario de Santiago, Choupana s/n, Santiago de Compostela, 15706, Spain.
Riveiro
Alberto
A
Department of Biochemistry, Hospital Clínico Universitario de Santiago, Choupana s/n, Santiago de Compostela, 15706, Spain.
Gude
Francisco
F
Epidemiology Unit, Hospital Clínico Universitario de Santiago, Choupana s/n, Santiago de Compostela, 15706, Spain.
D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D001794:Blood Pressure / Q000502:physiology*; D018450:Disease Progression; D004569:Electroencephalography; D004797:Enzyme-Linked Immunosorbent Assay; D005342:Fibrinolysis / Q000502:physiology; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000209:etiology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood*; D017286:Polysomnography; D011379:Prognosis; D011446:Prospective Studies; D012307:Risk Factors; D012720:Severity of Illness Index; D020181:Sleep Apnea, Obstructive / Q000097:blood* / Q000150:complications / Q000503:physiopathology; D011795:Surveys and Questionnaires
D015415:Biomarkers; D017395:Plasminogen Activator Inhibitor 1